Summit Therapeutics PLC says c-difficile trial slowed by coronavirus pandemic disruption
US infectious ailments agency BARDA is encouraging to fund the trial with a grant worth up to $seventy two.5mln. (NASDAQ:SMMT)...
US infectious ailments agency BARDA is encouraging to fund the trial with a grant worth up to $seventy two.5mln. (NASDAQ:SMMT)...
